The frequency of simultaneous mutations of TP53 with EGFR or KRAS is higher than 5% in both Western and Asian lung adenocarcinoma patients while it is significantly lower in lung squamous cell carcinoma patients of the two major groups.40 The gene discussed is KRAS; the disease is lung adenocarcinoma.